Clinical Trials in a Dish: The Potential of Pluripotent Stem Cells to Develop Therapies for Neurodegenerative Diseases

Annual Review of Pharmacology and Toxicology

Volumn 56, Issue , 2016, Pages 489-510

  Haston, Kelly M ^a   Finkbeiner, Steven ^a,b,c  

^a GLADSTONE INSTITUTE OF NEUROLOGICAL DISEASE   (United States)

^b Hellman Family Foundation Program in Alzheimer's Disease Research   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Clinical trials; Drug development; Human pluripotent stem cells; Neurodegeneration

Indexed keywords

AMYLOID BETA PROTEIN;

ARTICLE; BRAIN CELL; CELL DIFFERENTIATION; CENTRAL NERVOUS SYSTEM DISEASE; CORRELATION ANALYSIS; DEGENERATIVE DISEASE; DISEASE MODEL; DRUG SCREENING; DRUG SYNTHESIS; GENE EXPRESSION; HIGH CONTENT SCREENING; HIGH THROUGHPUT SCREENING; HUMAN; IN VITRO STUDY; MICROSCOPY; MOTONEURON; NONHUMAN; PERSONALIZED MEDICINE; PHENOTYPE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; ROBOTIC MICROSCOPY; SINGLE CELL ANALYSIS; STRATIFICATION; ANIMAL; BRAIN; CLINICAL TRIAL (TOPIC); PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; BRAIN; CLINICAL TRIALS AS TOPIC; HUMANS; NEURODEGENERATIVE DISEASES; PLURIPOTENT STEM CELLS;

EID: 84954122044     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev-pharmtox-010715-103548     Document Type: Article

References (150)

1. Kochanek KD, Murphy SL, Xu J, Arias E. 2014. Mortality in the United States, 2013. Data Brief 178, Natl. Cent. Health Stat., Hyattsville, MD
2. Jucker M. 2010. The benefits and limitations of animal models for translational research in neurodegenerative diseases. Nat. Med. 16(11):1210-14
3. Mitsumoto H, Brooks BR, Silani V. 2014. Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? Lancet Neurol. 13(11):1127-38
4. Finkbeiner S. 2010. Bridging the Valley of Death of therapeutics for neurodegeneration. Nat. Med. 16(11):1227-32
5. Mason AR, Ziemann A, Finkbeiner S. 2014. Targeting the low-hanging fruit of neurodegeneration. Neurology 83(16):1470-73
6. Mattson MP, Magnus T. 2006. Ageing and neuronal vulnerability. Nat. Rev. Neurosci. 7(4):278-94
7. Brown GC, Neher JJ. 2010. Inflammatory neurodegeneration and mechanisms of microglial killing of neurons. Mol. Neurobiol. 41(2-3):242-47
8. Gusella JF, Macdonald ME, Lee J-M. 2014. Genetic modifiers of Huntington's disease. Mov. Disord. 29(11):1359-65
9. Pankevich DE, Altevogt BM, Dunlop J, Gage FH, Hyman SE. 2014. Improving and accelerating drug development for nervous system disorders. Neuron 84(3):546-53
10. Mattson MP, Rychlik B, You JS, Sisken JE. 1991. Sensitivity of cultured human embryonic cerebral cortical neurons to excitatory amino acid-induced calcium influx and neurotoxicity. Brain Res. 542(1):97-106
11. Mertens J, Stuber K, Wunderlich P, Ladewig J, Kesavan JC, et al. 2013. APP processing in human pluripotent stem cell-derived neurons is resistant to NSAID-based secretase modulation. Stem Cell Rep. 1(6):491-98
12. Matus S, Medinas DB, Hetz C. 2014. Common ground: stem cell approaches find shared pathways underlying ALS. Cell Stem Cell 14(6):697-99
13. Gurney ME. 1994. Transgenic-mouse model of amyotrophic lateral sclerosis. N. Engl. J. Med. 331(25):1721-22
14. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, et al. 1996. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87(3):493-506
15. Li J-Y, Popovic N, Brundin P. 2005. The use of the R6 transgenicmousemodels of Huntington's disease in attempts to develop novel therapeutic strategies. NeuroRx 2(3):447-64
16. McGonigle P. 2014. Animal models of CNS disorders. Biochem. Pharmacol. 87(1):140-49
17. Perrin S. 2014. Preclinical research: make mouse studies work. Nature 507(7493):423-25
18. Clabough EBD. 2013. Huntington's disease: The past, present, and future search for disease modifiers. Yale J. Biol. Med. 86(2):217-33
19. Cooper-Knock J, Kirby J, Ferraiuolo L,Heath PR, Rattray M, Shaw PJ. 2012. Gene expression profiling in human neurodegenerative disease. Nat. Rev. Neurol. 8(9):518-30
20. Winner B, Marchetto MC,Winkler J, Gage FH. 2014. Human-induced pluripotent stem cells pave the road for a better understanding of motor neuron disease. Hum. Mol. Genet. 23(R1):R27-34
21. Jack CR Jr, Holtzman DM. 2013. Biomarker modeling of Alzheimer's disease. Neuron 80(6):1347-58
22. Vellas B, Carrillo MC, Sampaio C, Brashear HR, Siemers E, et al. 2013. Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: A report from the EU/US/CTAD Task Force. Alzheimer's Dement. 9(4):438-44
23. Thomson JA, Itskovitz-Eldor J, Shapiro SS, WaknitzMA, Swiergiel JJ, et al. 1998. Embryonic stem cell lines derived from human blastocysts. Science 282(5391):1145-47
24. Ben-Yosef D, Malcov M, Eiges R. 2008. PGD-derived human embryonic stem cell lines as a powerful tool for the study of human genetic disorders. Mol. Cell. Endocrinol. 282(1-2):153-58
25. FrumkinT,MalcovM,Telias M, Gold V, Schwartz T, et al. 2010. Human embryonic stem cells carrying mutations for severe genetic disorders. In Vitro Cell. Dev. Biol. Anim. 46(3-4):327-36
26. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, et al. 2007. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131(5):861-72
27. Okita K, Matsumura Y, Sato Y, Okada A, Morizane A, et al. 2011. A more efficient method to generate integration-free human iPS cells. Nat. Methods 8(5):409-12
28. Coatti GC, Beccari MS, Olávio TR, Mitne-Neto M, Okamoto OK, Zatz M. 2015. Stem cells for amyotrophic lateral sclerosis modeling and therapy: myth or fact? Cytometry 87(3):197-211
29. Zhang S-C, Wernig M, Duncan ID, Brustle O, Thomson JA. 2001. In vitro differentiation of transplantable neural precursors from human embryonic stem cells. Nat. Biotechnol. 19(12):1129-33
30. Krencik R, Weick JP, Liu Y, Zhang Z-J, Zhang S-C. 2011. Specification of transplantable astroglial subtypes from human pluripotent stem cells. Nat. Biotechnol. 29(6):528-34
31. Ring KL, Tong LM, Balestra ME, Javier R, Andrews-Zwilling Y, et al. 2012. Direct reprogramming of mouse and human fibroblasts into multipotent neural stem cells with a single factor. Cell Stem Cell 11(1):100-9
32. Vierbuchen T, Ostermeier A, Pang ZP, Kokubu Y, Sudhof TC,Wernig M. 2010. Direct conversion of fibroblasts to functional neurons by defined factors. Nature 463(7284):1035-41
33. Ambasudhan R, Talantova M, Coleman R, Yuan X, Zhu S, et al. 2011. Direct reprogramming of adult human fibroblasts to functional neurons under defined conditions. Cell Stem Cell 9(2):113-18
34. Meyer K, Ferraiuolo L, Miranda CJ, Likhite S, McElroy S, et al. 2014. Direct conversion of patient fibroblasts demonstrates non-cell autonomous toxicity of astrocytes to motor neurons in familial and sporadic ALS. PNAS 111(2):829-32
35. KeirsteadHS, Nistor G, Bernal G, Totoiu M, Cloutier F, et al. 2005. Humanembryonic stem cell-derived oligodendrocyte progenitor cell transplants remyelinate and restore locomotion after spinal cord injury. J. Neurosci. 25(19):4694-705
36. Hu B-Y, Du Z-W, Zhang S-C. 2009. Differentiation of human oligodendrocytes from pluripotent stem cells. Nat. Protoc. 4(11):1614-22
37. Almeida S, Gascon E, Tran H, Chou HJ, Gendron TF, et al. 2013. Modeling key pathological features of frontotemporal dementia with C9ORF72 repeat expansion in iPSC-derived human neurons. Acta Neuropathol. 126(3):385-99
38. WangS, Bates J,LiX, Schanz S,Chandler-Militello D, et al. 2013. HumaniPSC-derived oligodendrocyte progenitor cells can myelinate and rescue a mouse model of congenital hypomyelination. Stem Cell 12(2):252-64
39. Thoma EC, Merkl C, Heckel T, Haab R, Knoflach F, et al. 2014. Chemical conversion of human fibroblasts into functional Schwann cells. Stem Cell Rep. 3(4):539-47
40. Shi Y, Kirwan P, Smith J, Robinson HPC, Livesey FJ. 2012. Human cerebral cortex development from pluripotent stem cells to functional excitatory synapses. Nat. Neurosci. 15(3):477-86
41. Cooper O, Seo H, Andrabi S, Guardia-Laguarta C, Graziotto J, et al. 2012. Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease. Sci. Transl. Med. 4(141):141ra90
42. Kriks S, Shim J-W, Piao J, Ganat YM, Wakeman DR, et al. 2011. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature 480(7378):547-51
43. Wichterle H, Lieberam I, Porter JA, Jessell TM. 2002. Directed differentiation of embryonic stem cells into motor neurons. Cell 110(3):385-97
44. Singh Roy N, Nakano T, Xuing L, Kang J, Nedergaard M, Goldman SA. 2005. Enhancer-specified GFP-based FACS purification of human spinal motor neurons from embryonic stem cells. Exp. Neurol. 196(2):224-34
45. Giorgio FPD, Boulting GL, Bobrowicz S, Eggan KC. 2008. Human embryonic stem cell-derived motor neurons are sensitive to the toxic effect of glial cells carrying an ALS-causing mutation. Cell Stem Cell 3(6):637-48
46. Aubry L, Bugi A, Lefort N, Rousseau F, Peschanski M, Perrier AL. 2008. Striatal progenitors derived from human ES cells mature into DARPP32 neurons in vitro and in quinolinic acid-lesioned rats. PNAS 105(43):16707-12
47. Nicholas CR, Chen J, Tang Y, Southwell DG, ChalmersN, et al. 2013. Functional maturation of hPSCderived forebrain interneurons requires an extended timeline and mimics human neural development. Cell Stem Cell 12(5):573-86
48. Hu B-Y, Zhang S-C. 2009. Differentiation of spinal motor neurons from pluripotent human stem cells. Nat. Protoc. 4(9):1295-304
49. Chambers SM, Fasano CA, Papapetrou EP, Tomishima M, Sadelain M, Studer L. 2009. Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat. Biotechnol. 27(3):275-80
50. Qu Q, Li D, Louis KR, Li X, Yang H, et al. 2014. High-efficiency motor neuron differentiation from human pluripotent stem cells and the function of Islet-1. Nat. Commun. 5:3449
51. Maury Y,Come J, Piskorowski RA, Salah-MohellibiN,ChevaleyreV, et al. 2014. Combinatorial analysis of developmental cues efficiently converts human pluripotent stem cells into multiple neuronal subtypes. Nat. Biotechnol. 33(1):86-93
52. Tanaka A, Woltjen K, Miyake K, Hotta A, Ikeya M, et al. 2013. Efficient and reproducible myogenic differentiation from human iPS cells: prospects for modeling Miyoshi myopathy in vitro. PLOS ONE 8(4):e61540
53. Abujarour R, Bennett M, Valamehr B, Lee TT, Robinson M, et al. 2014. Myogenic differentiation of muscular dystrophy-specific induced pluripotent stem cells for use in drug discovery. Stem Cells Transl. Med. 3(2):149-60
54. Yasuno T, Osafune K, Sakurai H, Asaka I, Tanaka A, et al. 2014. Functional analysis of iPSC-derived myocytes from a patient with carnitine palmitoyltransferase II deficiency. Biochem. Biophys. Res. Commun. 448(2):175-81
55. Dupuis L, Loeffler JP. 2009. Neuromuscular junction destruction during amyotrophic lateral sclerosis: insights from transgenic models. Curr. Opin. Pharmacol. 9(3):341-46
56. Dadon-Nachum M, Ben-Yaacov K, Ben-Zur T, Barhum Y, Yaffe D, et al. 2014. Transplanted modified muscle progenitor cells expressing a mixture of neurotrophic factors delay disease onset and enhance survival in the SOD1 mouse model of ALS. J. Mol. Neurosci. 55(3):788-97
57. Thomson SR, Wishart TM, Patani R, Chandran S, Gillingwater TH. 2012. Using induced pluripotent stem cells (iPSC) to model human neuromuscular connectivity: promise or reality? J. Anat. 220(2):122-30
58. Israel MA, Yuan SH, Bardy C, Reyna SM, Mu Y, et al. 2012. Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. Nature 482(7384):216-20
59. HD iPSC Consortium. 2012. Induced pluripotent stem cells from patients with Huntington's disease show CAG-repeat-expansion-associated phenotypes. Cell Stem Cell 11(2):264-78
60. Nguyen HN, Byers B, Cord B, Shcheglovitov A, Byrne J, et al. 2011. LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. Cell Stem Cell 8(3):267-80
61. SkibinskiG,NakamuraK,CooksonMR, Finkbeiner S. 2014. MutantLRRK2toxicity in neurons depends on LRRK2 levels and synuclein but not kinase activity or inclusion bodies. J. Neurosci. 34(2):418-33
62. Burkhardt MF, Martinez FJ,Wright S, Ramos C, Volfson D, et al. 2013. A cellular model for sporadic ALS using patient-derived induced pluripotent stem cells. Mol. Cell. Neurosci. 56(C):355-64
63. NeumannM, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, et al. 2006. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314(5796):130-33
64. Serio A, Bilican B, Barmada SJ, Ando DM, Zhao C, et al. 2013. Astrocyte pathology and the absence of non-cell autonomy in an induced pluripotent stem cell model of TDP-43 proteinopathy. PNAS 110(12):4697-702
65. Juopperi TA, Kim W, Chiang C-H, Yu H, Margolis RL, et al. 2012. Astrocytes generated from patient induced pluripotent stem cells recapitulate features of Huntington's disease patient cells. Mol. Brain 5(1):17
66. Ebert AD, Yu J, Rose FF, Mattis VB, Lorson CL, et al. 2009. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 457(7227):277-80
67. Corti S,Nizzardo M, Simone C, Falcone M, NardiniM, et al. 2012. Genetic correction of human induced pluripotent stem cells from patients with spinal muscular atrophy. Sci. Transl. Med. 4(165):165ra162
68. Sareen D, Ebert AD, Heins BM, McGivern JV, Ornelas L, Svendsen CN. 2012. Inhibition of apoptosis blocks human motor neuron cell death in a stem cell model of spinal muscular atrophy. PLOS ONE 7(6):e39113
69. Chen H, Qian K, Du Z, Cao J, Petersen A, et al. 2014. Modeling ALS with iPSCs reveals that mutant SOD1 misregulates neurofilament balance in motor neurons. Cell Stem Cell 14(6):796-809
70. Wainger BJ, Kiskinis E, Mellin C, Wiskow O, Han SSW, et al. 2014. Intrinsic membrane hyperexcitability of amyotrophic lateral sclerosis patient-derived motor neurons. Cell Rep. 7(1):1-11
71. Egawa N, Kitaoka S, Tsukita K, Naitoh M, Takahashi K, et al. 2012. Drug screening for ALS using patient-specific induced pluripotent stem cells. Sci. Transl. Med. 4(145):145ra104
72. Alami NH, SmithRB, CarrascoMA, WilliamsLA, WinbornCS, et al. 2014. Axonal transport ofTDP-43 mRNA granules is impaired by ALS-causing mutations. Neuron 81(3):536-43
73. Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S. 2004. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431(7010):805-10
74. Arrasate M, Finkbeiner S. 2005. Automated microscope system for determining factors that predict neuronal fate. PNAS 102(10):3840-45
75. Bilican B, Serio A, Barmada SJ, Nishimura AL, Sullivan GJ, et al. 2012. Mutant induced pluripotent stem cell lines recapitulate aspects of TDP-43 proteinopathies and reveal cell-specific vulnerability. PNAS 109(15):5803-8
76. Barmada SJ, Serio A, Arjun A, Bilican B, Daub A, et al. 2014. Autophagy induction enhances TDP43 turnover and survival in neuronal ALS models. Nat. Chem. Biol. 10(8):677-85
77. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, et al. 2007. Induced pluripotent stem cell lines derived from human somatic cells. Science 318(5858):1917-20
78. Nishimura K, Sano M, Ohtaka M, Furuta B, Umemura Y, et al. 2011. Development of defective and persistent Sendai virus vector: A unique gene delivery/expression system ideal for cell reprogramming. J. Biol. Chem. 286(6):4760-71
79. Yamanaka S. 2012. Induced pluripotent stem cells: past, present, and future. Cell Stem Cell 10(6):678-84
80. Gore A, Li Z, Fung H-L, Young JE, Agarwal S, et al. 2011. Somatic coding mutations in human induced pluripotent stem cells. Nature 471(7336):63-67
81. Kim K, Doi A, Wen B,Ng K, Zhao R, et al. 2010. Epigenetic memory in induced pluripotent stem cells. Nature 467(7313):285-90
82. Lister R, Pelizzola M, Kida YS, Hawkins RD, Nery JR, et al. 2104. Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. Nature 470(7336):68-73
83. Bock C, Kiskinis E, Verstappen G, Gu H, Boulting G, et al. 2011. Reference maps of human ES and iPS cell variation enable high-throughput characterization of pluripotent cell lines. Cell 144(3):439-52
84. Inoue H, Nagata N, Kurokawa H, Yamanaka S. 2014. IPS cells: A game changer for future medicine. EMBO J. 33(5):409-17
85. Sareen D, O'Rourke JG, Meera P, Muhammad AKMG, Grant S, et al. 2013. Targeting RNA foci in iPSC-derived motor neurons from ALS patients with a C9ORF72 repeat expansion. Sci. Transl. Med. 5(208):208ra149
86. Grunseich C, Zukosky K, Kats IR,Ghosh L, Harmison GG, et al. 2014. Stem cell-derived motor neurons from spinal and bulbar muscular atrophy patients. Neurobiol. Dis. 70(C):12-20
87. Santostefano KE, Hamazaki T, Biel NM, Jin S, Umezawa A, Terada N. 2014. A practical guide to induced pluripotent stem cell research using patient samples. Lab. Investig. 95(1):4-13
88. 1000 Genomes Project Consortium. 2010. A map of human genome variation from population-scale sequencing. Nature 467(7319):1061-73
89. GajT,Gersbach CA, Barbas CF III. 2013. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol. 31(7):397-405
90. Fong H, Wang C, Knoferle J, Walker D, Balestra ME, et al. 2013. Genetic correction of tauopathy phenotypes in neurons derived from human induced pluripotent stem cells. Stem Cell Rep. 1(3):226-34
91. Ding Q, Lee Y-K, Schaefer EAK, Peters DT, Veres A, et al. 2013. A TALEN genome-editing system for generating human stem cell-based disease models. Cell Stem Cell 12(2):238-51
92. Mandal PK, Ferreira LMR, Collins R,Meissner TB, Boutwell CL, et al. 2014. Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9. Stem Cell 15(5):643-52
93. Ebert AD, Shelley BC, Hurley AM, Onorati M, Castiglioni V, et al. 2013. EZ spheres: A stable and expandable culture system for the generation of pre-rosette multipotent stem cells from human ESCs and iPSCs. Stem Cell Res. 10(3):417-27
94. Woodard CM, Campos BA, Kuo S-H, NirenbergMJ, Nestor MW, et al. 2014. iPSC-derived dopamine neurons reveal differences between monozygotic twins discordant for Parkinson's disease. Cell Rep. 9(4):1173-82
95. Muratore CR, Srikanth P, Callahan DG, Young-Pearse TL. 2014. Comparison and optimization of hiPSC forebrain cortical differentiation protocols. PLOS ONE 9(8):e105807
96. Humbert S. 2010. Is Huntington disease a developmental disorder? EMBO Rep. 11(12):899
97. Miller JD, Ganat YM, Kishinevsky S, Bowman RL, Liu B, et al. 2013. Human iPSC-based modeling of late-onset disease via progerin-induced aging. Cell Stem Cell 13(6):691-705
98. KondoT, AsaiM,Tsukita K, Kutoku Y, Ohsawa Y, et al. 2013. Modeling Alzheimer's disease with iPSCs reveals stress phenotypes associated with intracellular A and differential drug responsiveness. Cell Stem Cell 12(4):487-96
99. Liu G-H, Barkho BZ, Ruiz S, Diep D, Qu J, et al. 2011. Recapitulation of premature ageing with iPSCs from Hutchinson-Gilford progeria syndrome. Nature 472(7342):221-25
100. Nakano T, Ando S, Takata N, Kawada M, Muguruma K, et al. 2012. Self-formation of optic cups and storable stratified neural retina from human ESCs. Cell Stem Cell 10(6):771-85
101. Lancaster MA, Renner M, Martin C-A,Wenzel D, Bicknell LS, et al. 2014. Cerebral organoids model human brain development and microcephaly. Nature 501(7467):373-79
102. Singh VK, Kalsan M, Kumar N, Saini A, Chandra R. 2015. Induced pluripotent stem cells: Applications in regenerative medicine, disease modeling, and drug discovery. Front. Cell Dev. Biol. 3:2
103. Solomon S, Pitossi F, RaoMS. 2015. Banking on iPSC-is it doable and is it worthwhile. Stem Cell Rev. Rep. 11(1):1-10
104. Studer L, Desbordes SC. 2012. Adapting human pluripotent stem cells to high-throughput and highcontent screening. Nat. Protoc. 8(1):111-30
105. Engle SJ, Puppala D. 2013. Integrating human pluripotent stem cells into drug development. Cell Stem Cell 12(6):669-77
106. Zanella F, Lorens JB, Link W. 2010. High content screening: Seeing is believing. Trends Biotechnol. 28(5):237-45
107. Rubin LL, Haston KM. 2011. Stem cell biology and drug discovery. BMC Biol. 9(1):42
108. SwinneyDC, Anthony J. 2011. Howwere new medicines discovered? Nat. Rev. Drug Discov. 10(7):507-19
109. Daub A, Sharma P, Finkbeiner S. 2009. High-content screening of primary neurons: ready for prime time. Curr. Opin. Neurobiol. 19(5):537-43
110. Sharma P, Ando DM, Daub A, Kaye JA, Finkbeiner S. 2012. High-throughput screening in primary neurons. Methods Enzymol. 506:331-60
111. McGivern JV, Ebert AD. 2014. Exploiting pluripotent stem cell technology for drug discovery, screening, safety, and toxicology assessments. Adv. Drug Deliv. Rev. 69-70(C):170-78
112. Engle SJ, Vincent F. 2014. Small molecule screening in human induced pluripotent stem cell-derived terminal cell types. J. Biol. Chem. 289(8):4562-70
113. Moffat J, Sabatini DM. 2006. Building mammalian signalling pathways with RNAi screens. Nat. Rev. Mol. Cell Biol. 7(3):177-87
114. Edwards BS,Oprea T, Prossnitz ER, Sklar LA. 2004. Flow cytometry for high-throughput, high-content screening. Curr. Opin. Chem. Biol. 8(4):392-98
115. Sklar L, Carter M, Edwards B. 2007. Flow cytometry for drug discovery, receptor pharmacology and high-throughput screening. Curr. Opin. Pharmacol. 7(5):527-34
116. Li F, Yin Z, Jin G, Zhao H, Wong STC. 2013. Chapter 17: bioimage informatics for systems pharmacology. PLOS Comp. Biol. 9(4):e1003043
117. Meijering E, Dzyubachyk O, Smal I. 2012. Methods for cell and particle tracking. Methods Enzymol. 504:183-200
118. Steward O, Balice-Gordon R. 2014. Rigor or mortis: best practices for preclinical research in neuroscience. Neuron 84(3):572-81
119. GalimbertiD, Scarpini E. 2012. Clinical phenotypes and genetic biomarkers of FTLD. J. Neural Transm. 119(7):851-60
120. Finkbeiner S, Frumkin M, Kassner PD. 2015. Cell-based screening: extracting meaning from complex data. Neuron 86(1):160-74
121. Klein JP, Moeschberger ML. 1995. Techniques for censored and truncated data. Lifetime Data Anal. 1(2):195-204
122. Tsvetkov AS, Miller J, Arrasate M, Wong JS, Pleiss MA, Finkbeiner S. 2010. A small-molecule scaffold induces autophagy in primary neurons and protects against toxicity in a Huntington diseasemodel. PNAS 107(39):16982-87
123. Barmada SJ, Skibinski G, Korb E, Rao EJ, Wu JY, Finkbeiner S. 2010. Cytoplasmic mislocalization of TDP-43 is toxic to neurons and enhanced by a mutation associated with familial amyotrophic lateral sclerosis. J. Neurosci. 30(2):639-49
124. Koyanagi-Aoi M, Ohnuki M, Takahashi K, Okita K, Noma H, et al. 2013. Differentiation-defective phenotypes revealed by large-scale analyses of human pluripotent stem cells. PNAS 110(51):20569-74
125. Choi SH, Kim YH, Hebisch M, Sliwinski C, Lee S, et al. 2014. A three-dimensional human neural cell culture model of Alzheimer's disease. Nature 515(7526):274-78
126. Zhang QC, Yeh T-L, Leyva A, Frank LG, Miller J, et al. 2011. A compact model of Huntingtin toxicity. J. Biol. Chem. 286(10):8188-96
127. Kiskinis E, Sandoe J, Williams LA, Boulting GL, Moccia R, et al. 2014. Pathways disrupted in human ALS motor neurons identified through genetic correction of mutant SOD1. Cell Stem Cell 14(6)781-95
128. Mitne-Neto M, Machado-Costa M, Marchetto MCN, Bengtson MH, Joazeiro CA, et al. 2011. Downregulation of VAPB expression in motor neurons derived from induced pluripotent stem cells of ALS8 patients. Hum. Mol. Genet. 20(18):3642-52
129. Nihei Y, Ito D, Okada Y, AkamatsuW, Yagi T, et al. 2013. Enhanced aggregation of androgen receptor in induced pluripotent stem cell-derived neurons from spinal and Bulbar muscular atrophy. J. Biol. Chem. 288(12):8043-52
130. Cortes CJ, Miranda HC, Frankowski H, Batlevi Y, Young JE, et al. 2014. Polyglutamine-expanded androgen receptor interferes with TFEB to elicit autophagy defects in SBMA. Nat. Neurosci. 17(9):1180-89
131. Saporta MA, Dang V, Volfson D, Zou B, Xie XS, et al. 2015. Axonal Charcot-Marie-Tooth disease patient-derived motor neurons demonstrate disease-specific phenotypes including abnormal electrophysiological properties. Exp. Neurol. 263(C):190-99
132. Havlicek S, Kohl Z, Mishra HK, Prots I, Eberhardt E, et al. 2014. Gene dosage-dependent rescue of HSP neurite defects in SPG4 patients' neurons. Hum. Mol. Genet. 23(10):2527-41
133. Denton KR, Lei L, Grenier J, Rodionov V, Blackstone C, Li X-J. 2014. Loss of spastin function results in disease-specific axonal defects in human pluripotent stem cell-based models of hereditary spastic paraplegia. Stem Cells 32(2):414-23
134. Johnson-Kerner BL, Ahmad FS, Diaz AG, Greene JP, Gray SJ, et al. 2015. Intermediate filament protein accumulation in motor neurons derived from giant axonal neuropathy iPSCs rescued by restoration of gigaxonin. Hum. Mol. Genet. 24(5):1420-31
135. Xu C, TabebordbarM, Iovino S, Ciarlo C, Liu J, et al. 2013. A zebrafish embryo culture system defines factors that promote vertebrate myogenesis across species. Cell 155(4):909-21
136. Borchin B, Chen J, Barberi T. 2013. Derivation and FACS-mediated purification of PAX3+/PAX7+ skeletal muscle precursors from human pluripotent stem cells. Stem Cell Rep. 1(6):620-31
137. LancasterMA, Knoblich JA. 2014. Generation of cerebral organoids from human pluripotent stem cells. Nat. Protoc. 9(10):2329-40
138. Carri AD, OnoratiM,Lelos MJ,Castiglioni V, FaedoA, et al. 2012. Developmentally coordinated extrinsic signals drive human pluripotent stem cell differentiation toward authentic DARPP-32+medium-sized spiny neurons. Development 140(2):301-12
139. Kriks S, Shim J-W, Piao J, Ganat YM, Wakeman DR, et al. 2011. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature 480(7378):547-51
140. Krencik R, Weick JP, Liu Y, Zhang Z-J, Zhang S-C. 2011. Specification of transplantable astroglial subtypes from human pluripotent stem cells. Nat. Biotechnol. 29(6):528-34
141. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, et al. 2007. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131(5):861-72
142. Davis RL, Weintraub H, Lassar AB. 1987. Expression of a single transfected cDNA converts fibroblasts to myoblasts. Cell 51(6):987-1000
143. Li W, Jiang K, Ding S. 2012. Concise review: A chemical approach to control cell fate and function. Stem Cells 30(1):61-68
144. Liu X, Li F, Stubblefield EA, Blanchard B, Richards TL, et al. 2011. Direct reprogramming of human fibroblasts into dopaminergic neuron-like cells. Cell Res. 22(2):321-32
145. Caiazzo M, Dell'anno MT, Dvoretskova E, Lazarevic D, Taverna S, et al. 2011. Direct generation of functional dopaminergic neurons from mouse and human fibroblasts. Nature 476(7359):224-27
146. Victor MB, Richner M, Hermanstyne TO, Ransdell JL, Sobieski C, et al. 2014. Generation of human striatal neurons by microRNA-dependent direct conversion of fibroblasts. Neuron 84(2):311-23
147. Son EY, Ichida JK, Wainger BJ, Toma JS, Rafuse VF, et al. 2011. Conversion of mouse and human fibroblasts into functional spinal motor neurons. Cell Stem Cell 9(3):205-18
148. Caiazzo M, Giannelli S, Valente P, Lignani G, Carissimo A, et al. 2015. Direct conversion of fibroblasts into functional astrocytes by defined transcription factors. Stem Cell Rep. 4(1):25-36
149. Yang N, Zuchero JB, Ahlenius H,Marro S, Ng YH, et al. 2013. Generation of oligodendroglial cells by direct lineage conversion. Nat. Biotechnol. 31(5):434-39
150. Najm FJ, Zaremba A, Caprariello AV, Nayak S, Freundt EC, et al. 2011. Rapid and robust generation of functional oligodendrocyte progenitor cells from epiblast stem cells. Nat. Methods 8(11):957-62